Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH). FDA-approved for HIV-associated lipodystrophy; researched off-label in visceral fat reduction.
/)
Medically reviewed by Dr. Tuksaorn Suriyakan (Ping), Anti-Aging & Regenerative Medicine Physician
8 years of experience
/)
Tesamorelin is the most clinically validated GHRH analog for visceral adipose tissue reduction, with multiple peer-reviewed trials. Effects on liver fat and lipid profile have also been documented.
Our team confirms baseline metabolic and hormone status before starting, and tracks visceral fat and lipid markers over a 12 to 26-week protocol.
Tried diet and training for two years without moving belly fat. Tesamorelin protocol with labs every 8 weeks got it moving.
Doctor scoped the visceral fat angle specifically, not just weight. Helped me understand what we were actually treating.
Liver enzymes came down alongside the visceral fat. Wasn't expecting that, but the team had flagged it as a possible secondary benefit.
Our solutions for Weight‑Loss Management
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH). FDA-approved for HIV-associated lipodystrophy; researched off-label in visceral fat reduction.
/)
Tesamorelin is a stabilized GHRH analog with extended half-life. By increasing pulsatile GH release, it acts on visceral adipose tissue and lipid metabolism, with multiple peer-reviewed trials documenting the effect.
/)
Adults with improved visceral adiposity or metabolic markers that haven't responded to lifestyle alone. Doctor confirms cardiovascular and glucose-handling status first.
/)
Baseline metabolic panel, lipid profile, and waist or DEXA measurement are taken. A 12 to 26 week protocol follows, with re-measurement at the midpoint and end.
/)
Every Tesamorelin protocol starts with a full medical consultation and history review.
Prescriptions are filled by a licensed compounding pharmacy partner, not over-the-counter.
Follow-up consultations every four to six weeks to assess response and safety.
We frame Tesamorelin as a research-stage peptide and prescribe only when clinically appropriate.
Yes, for HIV-associated lipodystrophy. Use in non-HIV contexts (general visceral fat reduction) is off-label and doctor-supervised.
Both stimulate endogenous GH. Tesamorelin is stabilized for longer half-life and has stronger clinical data, particularly for visceral fat.
Visceral fat changes in trials typically appear by 12 weeks, with continued improvement at 26 weeks. Protocol length depends on goals.
Mild fluid retention can occur early; the team monitors and adjusts. Severe side effects are uncommon at therapeutic dosing.
Baseline metabolic panel, lipid profile, fasting glucose, IGF-1, and a body-composition measurement (waist circumference or DEXA). These set the baseline for tracking response over 12 to 26 weeks.
Patients with active malignancy, untreated diabetes with poor glycemic control, severe cardiovascular disease, or known GHRH hypersensitivity. Each case is reviewed during consultation.
/)
Dr. Tuksaorn (Dr. Ping) is an anti-aging and regenerative medicine physician with over 8 years of experience, focused on evidence-based wellness and personalized health programs that combine modern medical science with individualized care.
/)
/)
/)
/)